A second wave of checkpoint inhibitors is swelling fast, with speedy BeiGene leaping into a pivotal trial
Everybody wants their own checkpoint inhibitor, or so it may seem.
Now that the biology is thoroughly understood, we’re seeing a second wave of late-stage programs taking shape — each with their own niche markets in mind for disruption.
Today, you can add Beijing-based Beigene $BGNE to that list.
The biotech dosed their first patient with refractory classical Hodgkin lymphoma — or cHL — with their anti-PD-1 drug BGB-A317 in a pivotal study.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.